Related Experiment Videos
Astrocytic gliomas: MRI and pathological grade
S Asari1, T Makabe, S Katayama
1Department of Neurological Surgery, Okayama University Medical School, Japan.
Acta Medica Okayama
|December 1, 1993
Summary
Magnetic Resonance (MR) imaging features correlate with the pathological grade of astrocytic gliomas. Higher MR scores indicate increased tumor aggressiveness, aiding in diagnosis.
Area of Science:
- Neurology
- Radiology
- Oncology
Background:
- Astrocytic gliomas are a common type of brain tumor.
- Accurate grading of these tumors is crucial for treatment planning and prognosis.
- Distinguishing between different grades of astrocytic gliomas can be challenging using conventional methods.
Purpose of the Study:
- To investigate the correlation between Magnetic Resonance (MR) imaging configurations and the pathological grade of supratentorial astrocytic gliomas.
- To identify specific MR imaging features that can help differentiate between low-grade astrocytomas (LGAs), anaplastic astrocytomas (AAs), and glioblastoma multiformes (GBMs).
Main Methods:
- A study was conducted on 41 histologically verified supratentorial astrocytic gliomas using a 0.5T superconductive MR system.
- Gliomas were categorized into LGAs, AAs, and GBMs.
- MR imaging configurations were assessed based on nine criteria, scored, and statistically analyzed, including multiple regression analysis.
Main Results:
- A significant positive correlation was observed between MR imaging scores and pathological grades (p < 0.01-0.001).
- LGAs exhibited significantly lower MR scores compared to AAs and GBMs across multiple criteria.
- Heterogeneity, cyst or necrosis, edema or mass effect, and border definition were identified as key factors related to pathological grade.
Conclusions:
- MR imaging configurations are valuable in predicting the pathological grade of astrocytic gliomas.
- Specific imaging features like heterogeneity and contrast enhancement patterns can help distinguish between tumor grades.
- MR imaging can serve as a non-invasive tool to assess tumor aggressiveness and guide clinical management.